Available Until 1/27/2025

Ordering and Administering COVID-19 Therapeutics: Nirmatrelvir/Ritonavir and Molnupiravir

ACPE Numbers: 0204-0000-22-039-H01-P 
Release Date: February 10, 2022
Expiration Date: January 27, 2025
Activity Type: Application-based
CE Credits: 1.0 contact hours
Activity Fee: Free of charge

Activity Overview

Two oral antiviral medications, nirmatrelvir with ritonavir and molnupiravir, were recently authorized for emergency use to treat certain non-hospitalized patients with confirmed COVID-19. Join us for this one-hour activity to learn about the clinical trial data supporting the emergency-use authorizations of these antivirals. Speakers will also discuss the clinical considerations of each therapy, including precautions and contraindications, and how these antivirals fit into outpatient COVID-19 treatment regimens.

This activity was presented as a live webinar. Learners who claimed ACPE credit for these activities as part of that meeting should not claim ACPE credit again.


The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This activity was planned to meet the educational needs of pharmacists seeking information on clinical use of nirmatrelvir/ritonavir and molnupiravir for COVID-19 treatment.

At the conclusion of this activity, participants should be able to:

  • Describe the use of nirmatrelvir/ritonavir and molnupiravir in the treatment of COVID-19.
  • Describe contraindications and precautions of nirmatrelvir/ritonavir and molnupiravir therapy for COVID-19.

Introduction and PREP Act Implications
Michael Ganio, Pharm.D., M.S., BCSCP, BCPS, FASHP 

Molnupiravir Review
Molly Miller, Pharm.D.
Jeremy Tigh, Pharm.D. 

Nirmatrelvir/ritonavir Review
Monica Mahoney, Pharm.D., BCPS, BCIDP, FCCP 

Questions, Answers, Discussion

Monica Mahoney, Pharm.D., BCPS, BCIDP, FCCP
Clinical Pharmacy Specialist
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Dr. Monica Mahoney is a graduate of MCPHS University Boston, and completed PGY1 and PGY2-ID training at Tufts Medical Center. She is a clinical pharmacy specialist in the outpatient infectious diseases and OPAT clinics at Beth Israel Deaconess  Medical Center. She is an active member of many pharmacy and infectious diseases professional organizations, including ASHP, SIDP, and IDSA. You can find her on Twitter under the handle @mmPharmD. 

Molly Miller, Pharm.D.
Clinical Pharmacist
Nebraska Medicine
Omaha, Nebraska

Dr. Molly Miller is a clinical pharmacist in infectious diseases, antimicrobial stewardship, and outpatient parenteral antimicrobial therapy at Nebraska Medicine. Dr. Miller received her Bachelor of Arts in Chemistry in 2015 from the University of Nebraska - Lincoln and her Doctor of Pharmacy degree from the University of Nebraska Medical Center in 2019. She completed her PGY1 pharmacy practice residency and her PGY2 infectious diseases specialty residency at Nebraska Medicine.

Jeremy Tigh, Pharm.D.
PGY2 Specialty Practice Resident
Nebraska Medicine
Omaha, Nebraska

Dr. Jeremy Tigh received a BS in Cell/Molecular Biology from Utah State University and went on to get his Pharm.D. from the University of Utah in 2020. He completed a PGY1 residency at Nebraska Medicine, where he is also a current PGY2 resident in infectious diseases.

Michael Ganio, Pharm.D., M.S., FASHP 
Senior Director of of Pharmacy Practice and Quality
ASHP's Office of Practice Advancement 
Bethesda, Maryland

Dr. Ganio earned his Pharm.D. from the Rutgers University Ernest Mario School of Pharmacy and his Master's degree in Health-System Pharmacy Administration from The Ohio State University College of Pharmacy. He completed a PGY1 Pharmacy Practice residency at The Ohio State University Wexner Medical Center.  Prior to becoming the Senior Director of Pharmacy Practice and Quality in ASHP's Office of Practice Advancement, Dr. Ganio's previous roles included clinical pharmacy practice, pharmacy informatics and technology, and outpatient oncology operations. He has extensive knowledge of drug shortage management, pharmacy informatics and automation, medication billing and reimbursement, sterile compounding, and outpatient infusion and ambulatory-care practice models. Dr. Ganio has been invited to speak at several national and international conferences, including several meetings at the National Academies of Medicine on topics related to drug shortages and supply-chain challenges.

No one in control of the content of this activity has a relevant financial relationship (RFR) with an ineligible company. 

As defined by the Standards of Integrity and Independence in Accredited Continuing Education definition of ineligible company. All relevant financial relationships have been mitigated prior to the CPE activity.

Activities which can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations.  Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity. 

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.